| Nov 7 |
Cumberland: Q3 Earnings Snapshot
|
| Nov 7 |
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update
|
| Nov 6 |
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
|
| Nov 5 |
New Study Compares Caldolor® (ibuprofen injection) to ketorolac
|
| Oct 31 |
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS
|
| Aug 6 |
Cumberland: Q2 Earnings Snapshot
|
| Aug 6 |
Cumberland Pharmaceuticals Non-GAAP EPS of $0.01, revenue of $9.9M
|
| Aug 6 |
Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024
|
| Jul 30 |
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS
|
